Competing interests
CP has received grant funding from Pfizer and Daiichi Sankyo and honoraria from Pfizer, Roche, Daiichi Sankyo, Lilly, SeaGen, Novartis and Exact Sciences. CH-W has received honoraria for participation on advisory boards from Astra Zeneca, Eisai, Exact Sciences/Genomic Health, Lilly, Myriad, Novartis, Pfizer, Roche, Veracyte, Gilead and Seagen; and speaker honoraria from Astra Zeneca, Eisai, Exact Sciences/Genomic Health, Lilly, Myriad, Novartis, Pfizer, Roche, Veracyte and Gilead. DW has served on advisory boards for Pfizer, Roche, Astra Zeneca and Daiichi Sankyo and presented talks for Pfizer. GB has received financial support for attendance at conferences from Novartis and Roche. IM has received paid consultancy from Roche, Novartis, Pfizer, Eli Lilly, Pierre Fabre, Daiichi Sankyo, Astra Zeneca, and travel/Conference registration from Roche, Eli Lilly and Daichi Sankyo. MN has received Speaker’s fees and conference attendance money from Pfizer, Lilly and Novartis. MV has received grant funding from Amgen, Exact Sciences, Novartis/GSK, Pfizer and Roche; honoraria from Amgen, Astra Zeneca, Daiichi-Sankyo, Eisai, Exact Sciences, Lilly, Novartis/GSK, Pfizer and Roche; served on advisory boards/provided consultancy support for Amgen, Astra Zeneca, Daiichi-Sankyo, Eisai, Exact Sciences, Lilly, Merck, Novartis/GSK, Pfizer, Roche and Seagen. JE is an employee of Open Health Ltd, doing business as Open Health. CD is an employee of Pfizer UK and is a sponsor of this study; RC is an employee of Pfizer UK, a sponsor of the study and, as an employee, holds stock in Pfizer UK. AM, EM and AB declare no potential competing interests.